The defining pathological hallmark of Alzheimer\'s disease (AD) is the accumulation of amyloid-*β* protein (A*β*) in brain associated with tau pathology, synapse loss, cytoskeletal aberrations, mitochondrial dysfunction, and cognitive decline. Soluble oligomeric forms of A*β* are thought to be the most toxic species, resulting in synaptic loss and downstream neurotoxicity.^[@bib1]^ An early and consistent impairment secondary to A*β* oligomer treatment in primary neurons is the shrinkage of dendritic spines^[@bib2]^ involving the rearrangement of filamentous actin (F-actin) cytoskeleton in spines and loss of spine-associated proteins such as postsynaptic density-95 (PSD95) and Drebrin,^[@bib3],\ [@bib4]^ as well as impaired mitochondrial function.^[@bib5],\ [@bib6]^ Studies have implicated an involvement of the F-actin-severing protein Cofilin in A*β*-induced dendritic spine changes,^[@bib3],\ [@bib4]^ accumulation of Cofilin--Actin aggregates/rods in AD brains,^[@bib7]^ and increased Cofilin activity in brains of AD patients.^[@bib8]^ Cofilin normally functions as a key regulator of Actin dynamics that destabilizes F-actin. Cofilin is inactivated by phosphorylation on Ser3 by LIM kinase 1 (LIMK1), whereas its dephosphorylation by Slingshot homology-1 (SSH1) activates Cofilin.^[@bib9],\ [@bib10],\ [@bib11]^ Upon oxidative stress and/or Ca^2+^ elevation,^[@bib9],\ [@bib12],\ [@bib13]^ SSH1 is activated and active Cofilin becomes oxidized on cysteine residues, resulting in rapid mitochondrial translocation to promote mitochondria-mediated apoptosis and induction of Cofilin--Actin pathology.^[@bib14],\ [@bib15]^ Despite the circumstantial evidence for the involvement of Cofilin in AD pathogenesis, no direct evidence thus far has been presented.

Heterodimeric integrins (*α*- and *β-*subunits) comprise major adhesion receptors that regulate multiple facets of cellular function, including adhesion, motility, survival, and synaptic plasticity.^[@bib16]^ A primary function of integrins is to link the extracellular matrix to the F-actin cytoskeleton via structural scaffolding proteins such as Talin and Vinculin.^[@bib17],\ [@bib18]^ Among several proposed surface A*β* oligomer receptors such as PrP^c^ (Prion protein (cellular))/mGluR5 (metabotropic glutamate receptor 5)^[@bib19],\ [@bib20]^ and paired immunoglobin-like receptor-B (Pir-B)^8^, it has been shown that *α*2/*β*1 and *α*v/*β*1-integrins are also required to mediate A*β*-induced apoptosis and impairment in LTP.^[@bib21],\ [@bib22]^ However, whether A*β* binds directly to integrins and how A*β* engagement alters downstream integrin function are unknown. In this study, we explored the mechanistic relationships among A*β*42~O~ (amyloid-*β* protein 1--42 oligomers), *β*1-integrin, and Cofilin activities *in vitro*, HT22 cells, primary neurons, and genetically modified mice. Here we show that A*β*42~O~ exhibits direct high-affinity binding *β*1-integrin, inducing its conformational alteration, loss of surface *β*1-integrin, and disruption of integrin-associated focal complexes (FCs), as well as mitochondrial and synaptic dysfunction via a pathway involving ROS-dependent activation of SSH1 and Cofilin.

Results
=======

A*β*42~O~ induces loss of cell surface *β*1-integrin but not TfR or PrP^c^ and reduces *β*1-integrin activation
---------------------------------------------------------------------------------------------------------------

We prepared A*β*1-42 oligomers (A*β*42~O~) as previously characterized.^[@bib23]^ These A*β*42~O~ preparations contained SDS-resistant dimers, trimers, and tetramers ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}). The indicated A*β*42~O~ concentrations, heretofore, are based on the monomer concentration. To determine whether A*β*42~O~ alters surface levels or activation status of *β*1-integrin, we plated the hippocampus-derived HT22 mouse cell line in the presence and absence of fibronectin (FN) coating, treated them with A*β*42~O~ for 2 h and performed cell surface biotinylation experiments. Cell surface *β*1-integrin normalized to total was significantly reduced by \~60% regardless of FN coating after A*β*42~O~ treatment without altering total *β*1-integrin, although FN coating also significantly increased surface *β*1-integrin ([Figures 1a and b](#fig1){ref-type="fig"}; and [Supplementary Figures S1B and C](#sup1){ref-type="supplementary-material"}). Although FN coating modestly, but significantly, increased surface/total transferrin receptor (TfR), A*β*42~O~ (1 *μ*M) had no significant effect on surface TfR ([Figures 1a and c](#fig1){ref-type="fig"}). Surface PrP^c^ was unaffected by either FN coating or A*β*42~O~ treatment ([Figures 1a and d](#fig1){ref-type="fig"}). In FN-coated coverslips, A*β*42~O~ (2 h) also significantly reduced total surface *β*1-integrin levels by \~45% and further reduced activated surface *β*1-integrin by \~75% as detected by the HUTS-4 antibody^[@bib24]^ in non-permeabilized cells ([Figures 1e and f](#fig1){ref-type="fig"}). In days *in vitro* (DIV)-14 fixed and permeabilized neurons, A*β*42~O~ treatment *per se* significantly reduced the FITC (fluorescein isothiocyanate)-HUTS-4-positive activated *β*1-integrin by \>50%, which was significantly prevented by the *β*1-integrin allosteric modulating antibody (MAB1965)^[@bib25]^ and the PrP^c^ function blocking antibody (6D11)^[@bib19]^ ([Figures 1g and h](#fig1){ref-type="fig"}).

*β*1-integrin allosteric modulation or activation reduces A*β*42~O~ binding to neurons, HT22 cells, and purified *β*1-integrin
------------------------------------------------------------------------------------------------------------------------------

We next assessed A*β*42~O~ binding to mature DIV21 hippocampal neurons by adding 100 nM FITC-A*β*42~O~ for 1 h at 37 °C with prior incubation (1 h) with control immunoglobulin G (IgG), MAB1965, or HUTS-4 monoclonal IgGs. As expected, FITC-A*β*42~O~ associated with dendrites and dendritic spines, and such binding was significantly reduced by MAB1965 IgG by \~50% ([Figures 2a and b](#fig2){ref-type="fig"}). The HUTS-4 IgG, which has been shown to enhance ligand binding to *β*1-integrin,^[@bib26]^ also significantly reduced FITC-A*β*42~O~ binding to neurons by \>60% ([Figures 2a and b](#fig2){ref-type="fig"}). As previously shown,^[@bib19]^ 6D11 IgG significantly reduced FITC-A*β*42~O~ binding to neurons by \~50% ([Figures 2a and b](#fig2){ref-type="fig"}). In *β1-integrin fl/fl* neurons (conditional knockout, cKO)^[@bib27]^ transduced with high-titer lentiviruses expressing Cre-monomeric red fluorescent protein (mRFP), FITC-A*β*42~O~ binding to neurons was significantly reduced by \>60% ([Figures 2c and d](#fig2){ref-type="fig"}) while reducing *β*1-integrin expression by \~80--90% ([Figure 2e](#fig2){ref-type="fig"}). We next determined whether A*β* binds directly to *β*1-integrin-Fc (extracellular domain fused with human IgG-Fc).^[@bib26]^ Biotin-A*β*42~O~ bound to purified *β*1-integrin-Fc ([Figure 2f](#fig2){ref-type="fig"}) coated on ELISA plates with high affinity in the presence of 5 mM MgCl~2~, which induces an intermediate open integrin conformation ([Figure 2g](#fig2){ref-type="fig"}; *K*~d~=11.3 nM based on monomer calculation). In the absence of cation, minimal binding of A*β*42~O~ to *β*1-integrin-Fc was detected and did not appreciably increase with increasing biotin-A*β*42~O~ ([Figure 2g](#fig2){ref-type="fig"}). Surprisingly, MnCl~2~ (0.5 mM), which induces the maximal open activation state of integrins,^[@bib26]^ failed to support A*β*42~O~ binding to *β*1-integrin-Fc ([Figure 2g](#fig2){ref-type="fig"}), indicating that A*β*42~O~ prefers an intermediate activation state of *β*1-integrin. Accordingly, FITC-A*β*42~O~ binding to HT22 cells was also significantly reduced in the presence of 0.5 mM MnCl~2~ or MAB1965 but not MgCl~2~ ([Figures 2h and i](#fig2){ref-type="fig"}). Unlike A*β*42~O~, A*β*42 monomers and fibrils bound poorly to *β*1-integrin-Fc ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

Essential role of *β*1-integrin in A*β*42~O~-induced cofilin activation and reciprocal requirement of cofilin in A*β*42~O~-induced depletion of surface *β*1-integrin and FCs
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A*β*42~O~ (2 h, 1 *μ*M) treatment to primary cortical neurons significantly induced Cofilin dephosphorylation/activation ([Figures 3a and b](#fig3){ref-type="fig"}). However, such Cofilin dephosphorylation was absent in *β*1-integrin cKO neurons transduced with Lenti-Cre-mRFP ([Figures 2a and b](#fig2){ref-type="fig"}). We next determined whether Cofilin *per se* is also required for the observed A*β*42~O~-induced depletion of cell surface *β*1-integrin in HT22 cells. A*β*42~O~ reduced surface *β*1-integrin, and Cofilin siRNA reduced Cofilin levels ([Figure 3c](#fig3){ref-type="fig"}). However, Cofilin siRNA increased surface *β*1-integrin levels and prevented the A*β*42~O~-induced reduction in surface *β*1-integrin ([Figure 3c](#fig3){ref-type="fig"}). Quantification of surface *β*1-integrin and PrP^c^ levels secondary to Cofilin siRNA demonstrated that Cofilin knockdown significantly increases the surface/total *β*1-integrin ratio without affecting surface/total PrP^c^ ratio ([Figures 3d and e](#fig3){ref-type="fig"}), similar to that observed with A*β*42~O~ treatment.

A direct consequence of *β*1-integrin internalization is the disruption of integrin and F-actin-associated FCs, structurally organized by Talin and Vinculin. We treated DIV14 cortical neurons or HT22 cells with or without A*β*42~O~ (1 *μ*M) and subjected them to sequential extraction of the cytosolic fraction on ice with the surfactant saponin, followed by extraction of membrane and cytoskeletal elements with SDS sample buffer (FC-enriched fraction). A*β*42~O~ saliently reduced FC-enriched but not cytosolic (cyto) Vinculin and Talin in primary neurons ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}) and HT22 cells ([Supplementary Figures S3B and C](#sup1){ref-type="supplementary-material"}). To observe focal Vinculin in a different way, we cultured primary hippocampal neurons to DIV21 and treated them with or without A*β*42~O~ for 2 h followed by staining for Vinculin and F-actin. Regardless of A*β*42~O~ treatment, Vinculin nearly completely co-localized with F-actin, and discrete puncta positive for both Vinculin and F-actin were seen in dendritic spines ([Figure 3f](#fig3){ref-type="fig"}). However, A*β*42~O~ exposure significantly reduced focal Vinculin immunoreactivity in spine-containing dendrites after subtracting the diffuse cytosolic stain in dendrites ([Figures 3f and g](#fig3){ref-type="fig"}). In 7-month wild-type (WT) mice, Vinculin immunoreactivity in the CA3 pyramidal neurons demonstrated punctate immunoreactivity throughout neuronal cell bodies, indicative of FCs, with little diffuse staining. However, in 7-month-old APP/PS1 transgenic littermates,^[@bib28]^ Vinculin immunoreactivity appeared markedly more diffuse and cytosolic in the CA3 pyramidal neurons ([Supplementary Figure S3D](#sup1){ref-type="supplementary-material"}), with significant 75% and \~50% reductions in area and size of focal Vinculin, respectively, in APP/PS1 mice compared with WT littermates ([Supplementary Figure S3E](#sup1){ref-type="supplementary-material"}).

A*β*42~O~ treatment (1 *μ*M) to WT neurons depleted focal Vinculin and Talin ([Figure 3h](#fig3){ref-type="fig"}). However, the same treatment in littermate *Cofilin*^+/−^ neurons did not significantly deplete Vinculin and Talin in the FC-enriched fraction compared with WT neurons ([Figures 3h and i](#fig3){ref-type="fig"}). Accordingly, Cofilin knockdown also prevented A*β*42~O~-induced depletion of focal Vinculin in HT22 cells ([Supplementary Figures S4A and B](#sup1){ref-type="supplementary-material"}). Next, we stereotaxically injected 8-month-old APP/PS1 mice hippocampi with 2 *μ*l *β*1-integrin allosteric modulating/neutralizing antibody (MAB1965 prediluted 1 : 10) into the right hemisphere and control IgG (control ascites fluid prediluted 1 : 10) into the left hemisphere. Forty-eight hours post injection, MAB1965 IgG significantly increased focal Vinculin area and size in CA3 pyramidal neurons compared with control IgG in the contralateral hemisphere ([Figures 3j and k](#fig3){ref-type="fig"}), indicating that endogenous *β*1-integrin mediates APP/A*β*-induced depletion of focal Vinculin in brain.

Essential roles of cofilin and *β*1-integrin in A*β*42~O~-induced depletion of F-actin and F-actin-associated synaptic proteins in primary hippocampal neurons
--------------------------------------------------------------------------------------------------------------------------------------------------------------

The primary function of Cofilin is to sever F-actin, which promotes synaptic remodeling via accelerating Actin dynamics.^[@bib29]^ As A*β*42~O~ induced Cofilin activation, we cultured hippocampal neurons derived from *Cofilin*^+/−^ and WT littermate mice and cultured them to DIV21. A*β*42~O~ (1 *μ*M, 2 h) significantly depleted F-actin, Drebrin, and PSD95 in dendritic spines and spine-containing neurites of WT neurons ([Figures 4a and b](#fig4){ref-type="fig"}). However, the same A*β*42~O~ treatment had no significant effects in *Cofilin*^+/−^ neurons ([Figures 4a and b](#fig4){ref-type="fig"}), indicating that a critical threshold of endogenous Cofilin is required for A*β*42~O~-induced depletion of F-actin, Drebrin, and PSD95. Likewise, allosteric modulation of *β*1-integrin with MAB1965 IgG completely prevented the depletion of F-actin and PSD95 induced by A*β*42~O~ ([Figures 4c and d](#fig4){ref-type="fig"}), indicating that the *β*1-integrin-Cofilin pathway mediates A*β*42~O~-induced changes in F-actin and F-actin-associated postsynaptic proteins.

Requirement of SSH1 in A*β*42~O~-induced cofilin translocation to mitochondria and accumulation of mitochondrial cofilin in AD brains
-------------------------------------------------------------------------------------------------------------------------------------

Activated and oxidized Cofilin is known to translocate to mitochondria, where it induces mitochondrial dysfunction.^[@bib13],\ [@bib14]^ We treated HT22 cells with or without A*β*42~O~ (1 *μ*M) for 0, 2, and 4 h and fractionated intact mitochondria from cytosol. A*β*42~O~ rapidly increased the translocation of Cofilin to mitochondria, while decreasing phospho-Cofilin in the cytosol ([Figures 5a and b](#fig5){ref-type="fig"}). No phospho-Cofilin was detected in the mitochondrial fraction ([Figure 5a](#fig5){ref-type="fig"}), consistent with its activation requirement for translocation. RNAi-mediated knockdown of SSH1, the phosphatase that activates Cofilin,^[@bib10]^ significantly prevented A*β*42~O~-induced translocation of Cofilin to mitochondria together with increased Cofilin phosphorylation ([Figure 5c](#fig5){ref-type="fig"}), indicating that A*β*42~O~ activates and promotes Cofilin translocation to mitochondria via SSH1. We next isolated mitochondria from the frontal cortex of age-matched cognitively normal control and AD patients ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). In the absence of DTT in sample buffer (non-reducing), we detected cysteine-oxidized Cofilin monomers, dimers, trimers, and higher-order oligomers, which essentially all collapsed to the monomer form in the presence of DTT (reducing; [Figure 5d](#fig5){ref-type="fig"}). This banding pattern is similar to that observed from Cofilin--Actin rods, which also require activation and oxidation-induced disulfide bonding to form.^[@bib15]^ Total Cofilin (all four bands in non-reducing condition), oxidized Cofilin oligomers (dimers or larger), and Cofilin monomers were significantly increased in mitochondria of AD ([Figures 4d and e](#fig4){ref-type="fig"}), results that fulfill the prediction from cultured cells, and suggest that activated and oxidized mitochondrial Cofilin has a pathogenic role in AD.

A*β*42~O~-induced ROS production, mitochondrial dysfunction, and apoptosis via the *β*1-integrin--SSH1--Cofilin activation pathway
----------------------------------------------------------------------------------------------------------------------------------

HT22 cells were treated with A*β*42~O~ (1 *μ*M) with or without vehicle, NADPH oxidase (NOX) inhibitor, HUTS-4 IgG, or MAB1965 IgG and then subjected to live-cell imaging for JC-1, Mitosox-Red, and H2DCF (2′,7′-dichlorofluorescein). As expected, A*β*42~O~ treatment (1 *μ*M, 2 h) significantly decreased mitochondrial membrane potential (increased JC-1 green/red ratio), increased mitochondrial superoxide (Mitosox-Red), and increased ROS levels (H2DCF; [Figures 6a and b](#fig6){ref-type="fig"}; and [Supplementary Figure S6A](#sup1){ref-type="supplementary-material"}). However, co-incubation with HUTS-4, MAB1965, or NOX inhibitor significantly prevented such changes induced by A*β*42~O~, although the JC-1 membrane potential measure was not fully restored by these treatments ([Figures 6a and b](#fig6){ref-type="fig"} and [Supplementary Figure S6A](#sup1){ref-type="supplementary-material"}). Accordingly, MAB1965 significantly prevented A*β*42~O~-induced apoptosis in primary neurons and HT22 cells as assessed by Annexin V/PI staining ([Supplementary Figures S6B and D](#sup1){ref-type="supplementary-material"}). Similarly, Annexin V/PI staining also demonstrated significant induction of early (Annexin V) and late (PI) apoptosis after 24 h A*β*42~O~ (1 *μ*M) treatment, which was nearly completely blocked by SSH1 siRNA knockdown ([Figures 6c and d](#fig6){ref-type="fig"}), indicating that SSH1-dependent Cofilin activation is required for A*β*42~O~-induced apoptosis.

A key mechanism of Cofilin regulation is via the binding of SSH1 to 14-3-3, which renders SSH1 sequestered in an inactive state. However, the oxidation of 14-3-3 releases SSH1, thereby leading to SSH1 activation.^[@bib12],\ [@bib30]^ In 7-month-old APP/PS1 mice, SSH1/Cofilin complexes and 14-3-3/SSH1 complexes were significantly increased and decreased, respectively, compared with WT littermate mice ([Figures 6e and f](#fig6){ref-type="fig"}), indicating the release of SSH1 from 14-3-3 and association of SSH1 with Cofilin in APP/PS1 mice. Accordingly, phospho-Cofilin was significantly decreased in APP/PS1 mice, despite no apparent changes in total 14-3-3, SSH1, or Cofilin in TX-100 solubilized extracts ([Figures 6e and f](#fig6){ref-type="fig"}). A*β*42~O~ treatment also reduced 14-3-3/SSH1 complexes in HT22 cells, which was largely restored with prior treatment with MAB1965 or the potent anti-oxidant Trolox ([Supplementary Figure S7B](#sup1){ref-type="supplementary-material"}). Likewise, A*β*42~O~ treatment significantly increased SSH1/Cofilin complexes in HT22 cells ([Supplementary Figures S7C and D](#sup1){ref-type="supplementary-material"}). These results therefore demonstrate that APP/A*β* promotes Cofilin activation at least in part via the *β*1-integrin-ROS-14-3-3/SSH1 pathway.

Cofilin reduction rescues app/a*β*-induced gliosis and loss of synaptic proteins, as well as LTP and contextual memory deficits in APP/PS1 mice
-----------------------------------------------------------------------------------------------------------------------------------------------

We examined brains of 7-month-old APP/PS1, APP/PS1;*Cofilin*^+/−^, and WT littermate mice for neurodegenerative phenotypes, including glial fibrillary acidic protein (GFAP) for astrogliosis as well as PSD95 (postsynaptic) and Synapsin I (presynaptic) for synaptic integrity. As expected, APP/PS1 mouse hippocampi demonstrated significantly increased GFAP immunoreactivity throughout the hippocampus as well as diminished Synapsin I and PSD95 immunoreactivity within the stratum lucidium (synaptic terminating zone) of CA3 ([Figures 7a and b](#fig7){ref-type="fig"}). In contrast, APP/PS1;*Cofilin*^+/−^ mice showed significantly reduced GFAP immunoreactivity and increased Synapsin I and PSD95 immunoreactivities compared with APP/PS1 littermate mice, essentially indistinguishable from WT littermates ([Figures 7a and b](#fig7){ref-type="fig"}).

We next tested short-term and long-term synaptic plasticity from acute hippocampal slices prepared from 3-month-old WT, APP/PS1, and APP/PS1;*Cofilin*^+/−^ mice. The stimulating electrode was placed in the Schaffer collaterals of the hippocampus, and the recording electrode was positioned at the CA1 stratum radiatum below the pyramidal cell layer. As shown in [Figures 7c](#fig7){ref-type="fig"}, the input--output curves did not markedly differ among WT, APP/PS1, and *APP/PS1;Cofilin*^+/-^ slices. In paired pulse facilitation (PPF) experiments, we observed significant differences in fEPSP slope across genotypes among all interstimulus intervals ([Figure 7d](#fig7){ref-type="fig"}). However, correction for multiple comparisons showed that only APP/PS1;*Cofilin*^+/−^ and WT slices differed significantly at the 40-ms interstimulus interval ([Figure 7d](#fig7){ref-type="fig"}). For LTP measurements, we detected no differences in fEPSP slope among WT, APP/PS1, and APP/PS1;*Cofilin*^+/−^ slices at baseline ([Figure 7e](#fig7){ref-type="fig"}). However, after theta burst stimulation (TBS), we observed significant differences in fEPSP slope across genotypes for all time points ([Figure 7e](#fig7){ref-type="fig"}). Correction for multiple comparisons showed that APP/PS1 slices were significantly impaired in fEPSP slope compared with WT and APP/PS1;*Cofliln*^+/−^ slices at every time point up to 1 h, indicating that Cofilin reduction rescues the deficits in LTP in APP/PS1 mice.

We carried out fear conditioning tests (contextual and cued), in which 7-month-old WT, APP/PS1, and APP/PS1;*Cofilin*^+/−^ mice were trained on day 1 for both. On day 2, we tested mice for contextual and cued conditioning memory. We observed no significant differences between the genotypes in percent time spent freezing during the training phase ([Figure 7f](#fig7){ref-type="fig"}). However, we observed significant differences across genotypes in the percentage of time spent freezing during the hippocampus-dependent contextual fear conditioning test on day 2. Correction for multiple comparisons showed that WT and APP/PS1;*Cofilin*^+/−^ mice significantly spend more time freezing than APP/PS1 mice ([Figure 7g](#fig7){ref-type="fig"}). On the hippocampus-independent cued fear conditioning test, we did not observe significant differences in the percentage of time spent freezing times across genotypes ([Figure 7h](#fig7){ref-type="fig"}). We also did not find significant differences among the three genotypes in the rotarod or open-field (total distance traveled and total time spent immobile) tests ([Figures 7i--k](#fig7){ref-type="fig"}), indicating the absence of salient perturbations in generalized motor activity or coordination. Taken together, these results demonstrate that endogenous Cofilin is required to mediate the APP/PS1-induced deficits in synaptic plasticity as well as hippocampus-dependent contextual memory but not cued memory.

Discussion
==========

Molecular pathways that govern the production and neurotoxicity of A*β* are attractive therapeutic targets for AD. Although previous studies have shown Cofilin activation in AD brains and potential involvement of *β*1-integrin in A*β*-induced apoptosis,^[@bib7],\ [@bib8],\ [@bib21],\ [@bib22]^ it was unknown whether endogenous Cofilin *per se* and different *β*1-integrin conformers are required for molecular events leading to A*β*42~O~-induced neurodegeneration and how the *β*1-integrin--Cofilin signaling pathway mediates AD-relevant pathogenic processes.

In this study, we demonstrated for the first time that A*β*42~O~ induces the depletion of surface *β*1-integrin via its direct binding to low-intermediate activation conformers of *β*1-integrin, as detected by competition of A*β*42~O~ binding to neurons and HT22 cells with the *β*1-integrin activating antibody (HUTS-4) or MnCl~2~, both of which induce high conformational activation of *β*1-integrin.^[@bib24],\ [@bib26]^ Moreover, MnCl~2~ essentially eliminated A*β*42~O~ binding to purified *β*1-integrin-Fc. However, A*β*42~O~ did not bind to *β*1-integrin-Fc in the absence of Mg^2+^, suggesting that an intermediate/partially open conformation of integrin is required for binding. Although physiological ligands bind with high affinity to the highly active/open conformation of *β*1-integrin,^[@bib26]^ the human Ecovirus binds to the relatively inactive/closed integrin conformer,^[@bib31]^ similar to what we observed with A*β*42~O~. This finding raises the intriguing possibility of blocking A*β*42~O~-induced neurotoxic actions by conformational *β*1-integrin activation without compromising integrin function. In addition to preferentially binding to low-intermediate activation *β*1-integrin conformers, A*β*42~O~ also increased the propensity of *β*1-integrin to assume a lower-activation conformation, probably by preventing bound *β*1-integrin from assuming a high-activation state. As A*β*42~O~ reduced surface *β*1-integrin levels regardless of FN plating, A*β*42~O~ likely does not compete with most physiological ligands (i.e., FN) for integrin binding, as seen by its preference for binding to lower-activation conformation of *β*1-integrin. Although we focused on *β*1-integrin in this study, it is well known that *β*1-integrin functions in concert with various *α*-integrin subunits, such as *α*2 and *α*v, which have been shown to be involved in A*β* neurotoxicity,^[@bib21]^ as well as *α*6, which has been implicated in microglial phagocytosis of fibrillar A*β* together with *β*1.^[@bib32]^

Our observation that the PrP^c^ blocking antibody (6D11) significantly prevented A*β*42~O~-induced reduction in *β*1-integrin activation was somewhat surprising. However, it has been reported that PrP^c^ and Pir-B, both of which bind A*β*42~o~, negatively regulate *β*1-integrin activation and signaling,^[@bib33],\ [@bib34]^ raising the possibility that loss of these receptors can also interfere with A*β*42~O~ binding to *β*1-integrin in neurons. These receptors, including *β*1-integrin are typically clustered in pre- and postsynaptic membranes, and their activities are regulated by cross talk at multiple points of convergence by other transmembrane receptors. For example, PrP^c^-dependent activation of Fyn requires integrin engagement,^[@bib35]^ and glutamate signaling via NMDARs and AMPARs depends on various Integrin heterodimers.^[@bib16]^ Indeed, *β*1-integrin is also enriched in dendritic spines and is required for dendrite arborization, maintenance of synapses, and LTP.^[@bib36],\ [@bib37],\ [@bib38],\ [@bib39]^ In view of these observations, it is plausible that integrins operate physically and/or functionally in concert with other A*β*42~O~-binding receptors to mediate A*β*42~O~ binding and neurotoxicity.

Deletion of *β*1-integrin resulted in the failure of A*β*42~O~ to activate Cofilin. At the same time, Cofilin was also required for removal of surface *β*1-integrin, indicating that Cofilin normally has a role in the trafficking and/or internalization of *β*1-integrin. As such, we focused on *β*1-integrin and F-actin-associated structural focal components (Talin/Vinculin) and postsynaptic proteins known to function in concert with F-actin and synaptic remodeling, because the direct consequence of *β*1-integrin internalization is the disruption of the structural components of FCs (Talin and Vinculin), which anchor the cytoplasmic tail of *β*1-integrin to F-actin. Thus, it is likely that the F-actin severing activity of Cofilin is responsible for the removal of *β*1-integrin from the cell surface and the depletion of focal Talin/Vinculin by destabilizing or reducing the F-actin linkage to *β*1-integrin, changes which were directly analogous to F-actin *per se* and F-actin-regulated postsynaptic proteins (Drebrin and PSD95).

Cofilin activity is associated with dendritic spine growth and shrinkage during LTP and LTD, respectively,^[@bib40],\ [@bib41],\ [@bib42]^ and Cofilin regulates the trafficking of AMPA receptors in dendritic spines.^[@bib43]^ Therefore, A*β*42~O~-induced Cofilin activation and resultant F-actin severing/depolymerization also likely underlies the reduction in F-actin and synaptic proteins (PSD95 and Drebrin), both of which could be antagonized by Cofilin reduction or *β*1-integrin allosteric modulation. *β*-Arrestin 2 recruits Cofilin to dendritic spines upon NMDA receptor activation to control the remodeling of spines, and *β*-Arrestin 2 knockout neurons are resistant to A*β*-induced dendritic spine loss through spatial control of Cofilin activation.^[@bib44]^ Likewise, *Cofilin*^+/−^ neurons were resistant to A*β*-induced depletion of postsynaptic proteins. In view of these observations, it is plausible that Cofilin reduction prevents the sustained over-activation of Cofilin by A*β* oligomers to mitigate the loss of postsynaptic proteins and the deficits in LTP.

Our findings indicated that A*β*42~O~-induced and *β*1-dependent Cofilin activation, mitochondrial dysfunction, and apoptosis require endogenous SSH1 at least in part via ROS and 14-3-3. This is consistent with the induction of ROS production by NOX via Rac1-mediated signaling downstream of integrin,^[@bib45]^ A*β*42~O~--induced Cofilin--Actin pathology via a NOX/PrP^c^-dependent manner,^[@bib46]^ activation of SSH1 by oxidation of 14-3-3,^[@bib12]^ A*β*-induced oxidation of 14-3-3,^[@bib47],\ [@bib48]^ and Cofilin-dependent mitochondrial dysfunction downstream of oxidative stress.^[@bib13]^ Although a recent study reported that fibrillar A*β*42 can activate LIMK1 via p21-activated kinase 1, they also observed increased Cofilin dephosphorylation; therefore, A*β* oligomers and fibrils may impact the Cofilin activation pathway via similar but also divergent mechanisms.^[@bib49]^ In addition to ROS-dependent activation of SSH1, it is likely that A*β*42~O~ can also activate Cofilin via a mechanism involving an increase in cytosolic Ca^2+^, which in part may be mediated by the PrP^c^-mGluR5 complex,^[@bib20]^ as Calcineurin dephosphorylates and activates SSH1.^[@bib50]^ We have also shown that RanBP9, which activates Cofilin, also impairs mitochondrial Ca^2+^ buffering and mitochondrial homeostasis in a Cofilin-dependent manner.^[@bib13],\ [@bib51],\ [@bib52]^

In summary, our findings indicate that a molecular pathway involving SSH1--Cofilin activation via direct engagement of lower-activation conformers of *β*1-integrin is essential for both A*β*42~O~-induced mitochondrial and synaptic dysfunction in AD. Therefore, promoting *β*1-integrin activation and/or inhibiting excessive Cofilin activation (i.e., SSH1 inhibition) represent potentially viable and novel therapeutic strategies to combat AD pathogenesis.

Materials and Methods
=====================

Cells, cDNA constructs, siRNA sequences, and transfections
----------------------------------------------------------

Hippocampus-derived HT22 and CHO (Chinese Hamster Ovary) 7WD10 cells were maintained in DMEM containing 10% FBS. HT22 and CHO7WD10 cell lines were obtained from Professor David Schubert (Salk Institute, San Diego) and Professor Edward Koo (UC, San Diego). Green fluorescent protein--Vinculin construct was obtained from Professor Ballestrem (University of Manchester, UK).^[@bib53]^ The *β*1-Fc integrin construct was obtained from Dr. Mould at the University of Manchester (UK). The *β*1-integrin-Fc construct encodes residues 1-708 (*β*1 extracellular region) fused in-frame to the hinge regions and CH2 and CH3 domains of human IgG*γ*1.^[@bib26]^ RNAi sequences targeting Cofilin (5′-GGAGGACCUGGUGUUCAUC-3′) and SSH1 (5\'-GAGGAGCUGUCCCGAUGAC-3\') were obtained from GE Dharmacon (Lafayette, CO, USA). All cells were transfected for 48 h using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions with either cDNA expression constructs, empty vector controls, siRNA duplexes, or control single-stranded denatured control siRNAs before performing biochemical and/or immunocytochemical assays. All siRNAs were transfected at a final concentration of 100 nM. Cortical and hippocampal primary neurons were derived from postnatal day 0 (P0) pups and grown on Poly-[d]{.smallcaps}-lysine-coated coverslips or plates as previously described.^[@bib51]^

Antibodies and reagents
-----------------------

Antibodies to APP (6E10, Covance, Princeton, NJ, USA), sAPP*α* (IBL-America, Minneapolis, MN, USA), sAPP*β* (IBL-America), *β*1-integrin (M-106, Santa Cruz Biotechnology, Dallas, TX, USA), activated *β*1-integrin (HUTS-4, EMD Millipore, Billerica, MA, USA), allosteric *β*1-integrin neutralizing (MAB1965, EMD Millipore), 6D11 (Santa Cruz), Talin (H-300, Santa Cruz Biotechnology), Vinculin (hVIN-1, Sigma-Aldrich, St. Louis, MO, USA), Cofilin (D3F9, Cell Signaling, Danvers, MA, USA), phospho-Cofilin (77G2, Cell Signaling), SSH1 (SP1711, ECM Biosciences, Versailles, KY, USA), pan-14-3-3- (Santa Cruz Biotechnology), Actin (AC-74, Sigma-Aldrich), Tubulin (TU-02, Santa Cruz Biotechnology), A*β* (D5XD2, Cell Signaling), biotin (B7653, Sigma-Aldrich), GFAP (Invitrogen), Synapsin I (Invitrogen), PSD95 (Abcam, Cambridge, MA, USA), Drebrin (Abcam), MAP2 (EMD Millipore), HRP-linked secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA), and fluorescently labeled secondary antibodies (Invitrogen) were obtained from the indicated sources. The mouse monoclonal anti-RanBP9 antibody was a generous gift from Professor Elizabetta Bianchi (Pasteur Institute, France). Trolox (Cayman, Ann Arbor, MI, USA), JC-1 (Invitrogen), Mitosox-Red (Invitrogen), H2DCF (Invitrogen), NOX inhibitor III (EMD Millipore) were purchased from the indicated sources. Synthetic A*β*1-42 and FITC-A*β*1-42, and biotin-A*β*1-42 peptides were purchased from American Peptide (Sunnyvale, CA, USA). A*β*1-42 oligomers and fibrils were prepared precisely as previously characterized.^[@bib23]^ Briefly, A*β*1-42 powder was dissolved in HFIP at 1 mM for 30 min at room temperature, aliquoted to Eppendorf tubes, allowed to evaporate overnight in fume hood, and subjected to speed vacuum for 1 h to remove traces of HFIP or moisture. To prepare A*β* oligomers, A*β*1-42 film was then dissolved in DMSO (5 mM), and F-12 cell culture medium (without phenol) was added to a final concentration of 100 *μ*M A*β*1-42 and incubated at 4 °C for 24 h.

Cell/tissue lysis and immunoblotting
------------------------------------

Cultured cells or brain homogenates were lysed with lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 2 mM EDTA, and 1% Triton X-100) unless stated otherwise. For separation of cytosolic *versus* focal adhesion-enriched (F) fractions, cytosolic proteins were first released with saponin buffer (0.1% saponin, 25 mM HEPES, and 75 mM potassium acetate) for 10 min on ice followed by extraction of remaining proteins by 2 × SDS sample buffer and sonication.^[@bib54],\ [@bib55]^ For isolation of mitochondria, mitochondrial isolation kit (Thermo Scientific, Rockford, IL, USA) was used according to the manufacturer\'s instructions for cultured cells. Protein quantification was performed by a colorimetric detection reagent (BCA protein assay, Pierce, Rockford, IL, USA). Equal amounts of protein were subjected to SDS-PAGE and transferred to nitrocellulose membranes for immunoblotting. After probing with the primary antibody, the corresponding peroxidase-conjugated secondary antibody was detected by ECL western blot reagents (Pierce). ECL images were captured by the Fuji LAS-4000 imager (LAS-4000, Pittsburgh, PA, USA) and quantified using the ImageJ software (NIH ImageJ, Bethesda, MD, USA).

Cell surface biotinylation assay
--------------------------------

Surface biotinylation assays were performed as we previously documented.^[@bib56]^ Briefly, confluent cells in six-well plates were washed three times in phosphate-buffered saline (PBS) and treated with 2.0 mg/ml sulfo-NHS-LC-biotin in PBS, pH 8.0 under gentle shaking for 1 h on ice. The cells were then washed three times in PBS and lysed in 1% Triton X-100 lysis buffer. Biotinylated proteins were isolated by pulldown with anti-biotin antibody together with anti-mouse agarose beads (American Qualex, San Clemente, CA, USA). APP (6E10, Covance) and *β*1-integrin (M-106, Santa Cruz Biotechnology) within anti-biotin immune complexes were detected by immunoblotting with the indicated antibodies.

Annexin V/PI apoptosis assay
----------------------------

To examine the stage of apoptotic cells, measurements were carried out using FACS Calibur (BD Bioscience, San Jose, CA, USA) or fluorescence microscopy. Cells were either trypsinized/collected stained in solution or directly stained on glass coverslips with Annexin V-fluorescein and PI for 20 min at 25°C in the dark state using the FITC Annexin V apoptosis detection kit I (BD, San Diego, CA, USA). After washing with ice-cold PBS, cells were measured by flow cytometry or by fluorescence microscopy as previously described.^[@bib51]^

FITC-A*β*1-42 oligomer binding to primary neurons and HT22 cells
----------------------------------------------------------------

DIV21 hippocampal neurons or HT22 cells were incubated with FITC-A*β*42~O~ (100 nM) for 1--2 h. Cells were then washed extensively with PBS, fixed with 4% paraformaldehyde, stained with DAPI, and fluorescent images were acquired using the Olympus FV10i confocal microscope (Olympus Corp., Tokyo, Japan). All comparison images were acquired with identical laser intensity, exposure time, and filter. Adjustments to the brightness/contrast were applied equally to all comparison images.

Purification of *β*1-integrin-Fc and binding to A*β*42~O~
---------------------------------------------------------

CHO cells in 10cm plates were transfected with 12 *μ*g *β*1-integrin-Fc constructs for 48 h. Conditioned medium was collected for 24 h thereafter and spun for 5 min at 1000 × *g*. Proteins in expressed in conditioned medium were captured by the anti-Fc affinity column and eluted by several rounds. Ninety-six-well plates were coated with goat anti-human-Fc at a concentration of 5 *μ*g/ml in DPBS (50 *μ*l per well) for 16 h. Wells were washed with DPBS (100 *μ*l per well) and then blocked for 1 h with 100 *μ*l of 5% (w/v) bovine serum albumin (BSA), 150 mM NaCl, 0.05% (w/v) NaN~3~, and 25 mM Tris-Cl, pH 7.4 (blocking buffer). The blocking solution was removed, and wells were then washed three times with 100 *μ*l of 150 mM NaCl and 25 mM Tris-Cl, pH 7.4, and containing 1 mg/ml BSA (washing buffer). Purified *β*1-Fc was added to the plate incubated at room temperature for 1 h. Wells were washed three times in washing buffer, and biotin-labeled A*β*1-42 (50 *μ*l, monomer, oligomer, or fibrils at the indicated concentrations) were added for 1 h at 37 °C. After washing wells three times in washing buffer, streptavidin-HRP (1 : 2000 dilution in washing buffer, Cell Signaling) was added (50 *μ*l per well) for 30 min at room temperature. Wells were washed four times in washing buffer, and color was developed using the TMB substrate (Cell Signaling) and read at 450 nM wavelength. Background A*β* binding to conditioned medium from mock-transfected CHO cells was subtracted from all measurements (specific binding).

Mice and human samples
----------------------

APP/PS1, WT, *Cofilin*^+/−^, and *β*1-integrin fl/fl mice were all bred in the C57BL6 background for at least three generations before interbreeding with each other. APP/PS1 mice were obtained from Jackson Laboratory (Ben Harbor, ME, USA).^[@bib28]^ We generated *Cofilin*^+/−^ knockout mice from an embryonic stem cell gene trap clone originally made by Lexicon Genetics (Woodlands, TX, USA) and deposited into the MMRRC repository (UC, Davis). *Cofilin*^+/−^ mouse brains exhibited \~50% reduction in endogenous Cofilin protein in both hippocampus and cortex compared with littermate WT mice ([Supplementary Figure S8](#sup1){ref-type="supplementary-material"}). Although *Cofilin*^+/−^ mice were viable and fertile with no salient abnormalities, *Cofilin*^+/−^ × *Cofilin*^+/−^ crosses yielded no viable *Cofilin*^−/−^ pups (embryonic lethal). Detailed genotypic and phenotypic information about these mice are available (<http://www.informatics.jax.org/external/ko/lexicon/2682.html>). Information on *β*1-integrin *fl/fl* mice are also available (<http://jaxmice.jax.org/strain/004605.html>). Postmortem brain samples were obtained from the UC, Irvine, ADRC. Ages, gender, and PMI are indicated in [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}.

Immunofluorescence
------------------

Immunohistochemistry and immunocytochemistry were performed as previously described.^[@bib51]^ Briefly, animals were perfused with 4% paraformaldehyde in PBS, and the brains were post fixed in the same fixative for 24 h. The brains were then cryoprotected in 30% sucrose and sectioned (30 *μ*m) on a cryostat or microtome. For primary neurons and HT22 cells, cells were fixed in 4% paraformaldehyde for 15 min at room temperature. For cell surface protein detection only, Triton X-100 was omitted. After blocking with normal goat serum, primary antibodies were applied overnight at 4 °C, and secondary antibodies were applied for 45 min at room temperature, followed by counterstaining with Hoechst33342 or DAPI. Immunoreactivities were quantitated from every 12th serial section through an entire hippocampus or anterior cortex. In brain, focal Vinculin was separated from diffuse cytosolic Vinculin by using the 'thresholding\' function in ImageJ software, where the threshold was adjusted to convert the highest intensity signal from green to red while not altering the diffuse cytosolic Vinculin signal. The average area and size/puncta were quantitated with the ImageJ software. In primary neurons, vinculin immunoreactivity was quantified in dendrites and dendritic spines by subtracting diffuse cytosolic intensity in dendrites, which provides an internally controlled measure of focal vinculin *versus* diffuse cytosolic vinculin. All images were acquired with the Olympus FV10i confocal microscope and quantified using the Olympus Fluoview software (Olympus Corp.). All comparison images were acquired with identical laser intensity, exposure time, and filter. Adjustments to the brightness/contrast were applied equally to all comparison images.

JC-1, Mitosox-Red, and H2DCF imaging
------------------------------------

HT22 cells seeded in 24-well plates were treated with/without HUTS-4 (1 : 250), MAB1965 (1 : 250), or Nox inhibitor III (40 nM) for 45 min, then treated with or without A*β*42~O~ (1 *μ*M) for 2 h. For Mitosox-Red imaging, cells were then washed with PBS and Mitosox-Red was added to a final concentration of 5 *μ*M in PBS for 15 min at 37 °C, after which cells were washed with PBS, fixed, and imaged under the Olympus FV10i confocal microscope. For H2DCF imaging, after washing cells in PBS, H2DCF was added at a final concentration of 50 nM in HBSS for 15 min at 37 °C, followed by live-cell imaging at 37 °C with the Nikon Eclipse Ti fluorescence microscope (Nikon Instruments, Melville, NY, USA). For JC-1 imaging, after washing cells in PBS, JC-1 was added at a final concentration of 0.5 *μ*M in PBS and incubated for 15 min at 37 °C, followed by live-cell imaging at 37 °C with the Nikon Eclipse Ti fluorescence microscope. All comparison images were acquired with identical laser or mercury lamp intensity, exposure time, and filter. Adjustments to the brightness/contrast were applied equally to all comparison images.

Stereotaxic surgery
-------------------

Eight-month-old APP/PS1 mice were stereotaxically injected with 2 *μ*l of either control IgG (control ascites diluted 1 : 10 in PBS) into the left hemisphere or *β*1-integrin neutralizing IgG (MAB1965 ascites diluted 1 : 10 in PBS) into the right hemisphere of the hippocampus (AP 2.7, Lat −2.7, DV −3.0) using the convection-enhanced delivery method described previously.^[@bib57]^ Forty-eight hours later, mice were subjected to transcardial perfusion with 4% paraformaldehyde followed by tissue sectioning and immunohistochemistry.

Electrophysiology in mouse brain slices
---------------------------------------

Hippocampus slices were prepared from 3-month-old WT, APP/PS1, and APP/PS1;*Cofilin*^+/−^ mice and subjected to input/output curved, PPF, and LTP as previously described.^[@bib58]^ Briefly, animals were killed, and brains were harvested and sectioned horizontally (400 *μ*m) in ice-cold cutting solution (110 mM sucrose, 6 mM NaCl, 3 mM KCl, 26 mM NaHCO~3~, 1.25 mM NaH~2~PO~4~, 7 mM MgCl~2~, 0.5 mM CaCl~2~, and 10 g/l glucose, pH 7.3--7.4). The hippocampus was dissected and acclimated in 50:50 solution (cutting:artificial cerebrospinal fluid (ACSF)) for 10 min at room temperature. Further, the slices were transferred to ACSF (125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH~2~PO~4~, 0.26 mM NaHCO~3~, 1.2 mM MgCl~2~, 2.0 mM CaCl~2~, and 10 g/l glucose, pH 7.3--7.4, saturated with 95% O~2~ and 5% CO~2~). Slices were recovered in ACSF at room temperature at least 40 min, followed by a final incubation in ACSF for 1 h at 30 °C.

Extracellular field potential recording, LTP: The recording chamber was held at 30±0.5 °C with ACSF flow rate of 1 ml/min. The stimulating electrode was placed in the Schaffer collaterals of the hippocampus. The recording glass electrode loaded with ACSF was positioned at the CA1 stratum radiatum below the pyramidal cell layer. Stimulating pulses were generated by the Digidata 1322 A interface (Molecular Devices, Sunnyvale, CA, USA) and a stimulus isolator (model 2200; A-M Systems, Sequim, WA, USA) under control of Clampex 10.0 software (Molecular Devices). Field excitatory postsynaptic potentials (fEPSPs) were amplified using a differential amplifier (model 1800; A-M Systems), filtered at 1 kHz, and digitized at 10 kHz.

Input--output curve was generated by stepping stimulation amplitude from 1 to 15 mV. Stimulation amplitude that elicited half-maximal fEPSP was determined by the input--output curve, and stimulation rate of 0.05 Hz was used through the whole experiment. PPF, which is short-term plasticity, was evoked by two pulses with interpulse intervals from 20 to 300 ms. Percentage of the facilitation was calculated by dividing fEPSP slope elicited by the second pulse with the fEPSP slope elicited by the first pulse. LTP was induced by TBS (five trains of four pulses at 200 Hz separated by 200 ms, repeated six times with an inter-train interval of 10 s). LTP was sampled 60 min after the induction, and calculated by dividing the slope of 60 min post-induction responses with the average slope of 20 min baseline responses.

Fear conditioning, open field, and rotarod behavior
---------------------------------------------------

Fear conditioning (contextual and cued), rotarod, and open-field tasks were performed as previously described.^[@bib59]^ For fear conditioning, an aversive stimulus (in this case a mild foot shock, 0.5 mA) was paired with an auditory conditioned stimulus (white noise) within a novel environment. Training consisted of two mild shocks paired with two conditioned stimuli with a 3-min interval between each shock. Freezing on the training day in response to the foot shock was used as an estimate of learning during the acquisition trial. To test conditioning to the context, animals were re-introduced to the same training chamber for 6 min and freezing behavior was recording by tracking software (Any-maze, Wood Dale, IL, USA) every second. To test conditioning to the tone, animals were introduced to a novel context, consisting of a chamber with different shape, floor, and olfactory cues from the training chamber. Mice were scored for 3 min, before and after the tone in the same manner described above. Learning was assessed by measuring freezing behavior (i.e., motionless position) every second. The open field was used as a standard test of general activity. Briefly, animals were monitored for 15 min in a 40-cm^2^ open field with a video tracking software (Any-maze). General activity levels were evaluated by measurements of total distance traveled and total time immobile. Motor performance was evaluated by an accelerating rotarod apparatus with a 3-cm diameter rod starting at an initial rotation of 4 r.p.m. slowly accelerating to 40 r.p.m over 5 min. The time spent on the rod during each of four trials per day for 2 consecutive days was measured previously described in Brownlow *et al.*^[@bib60]^

Statistical analysis and graphs
-------------------------------

Statistical data were analyzed by the GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA, USA) using Student\'s *t*-test, one- or two-way ANOVA. One- or two-way ANOVA was followed by Tukey *post hoc* test. All quantitative graphs were expressed as mean±S.E.M. Differences were deemed significant when *P*\<0.05.
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![A*β*42~O~ induces loss of cell surface *β*1-integrin but not TfR or PrP^c^ and reduces *β*1-integrin activation. (**a**--**d**) HT22 cells plated with/without FN, treated with/without A*β*42~O~ (1 *μ*M, 2 h), subjected to surface biotinylation (surface), and direct immunoblotting (total) or immunoprecipitation for biotin (surface) and immunoblotting for the indicated proteins. (**b**--**d**) Quantification of normalized surface/total *β*1, TfR, and PrP^c^ (*n*⩾3 replicates, ANOVA, *post hoc* Tukey,\**P*\<0.05, ^\#^*P*\<0.0005). Error bar represent S.E.M. (**e** and **f**) HT22 cells treated with /without A*β*42~O~ and immunostained for total surface *β*1-integrin or activated surface *β*1-integrin (HUTS-4 antibody) without membrane permeabilization (*n*⩾4 replicates, *T*-test, \*\**P*\<0.005, ^\#^*P*\<0.0005). (**g** and **h**) Direct staining for activated *β*1-integrin (FITC-HUTS-4 antibody) in fixed and permeabilized DIV14 primary hippocampal neurons after treatment with/without A*β*42~O~ (1 *μ*M, 2 h) and/or control ascites IgG (1 : 250), MAB1965 (1 : 250), or 6D11 (1 : 50). (**h**) Quantification of FITC-HUTS-4 immunoreactivity (*n*=4 replicates, ANOVA, *post hoc* Tukey,\**P*\<0.05, \*\**P*\<0.005)](cdd20155f1){#fig1}

![*β*1-Integrin allosteric modulation or activation reduces A*β*42~O~ binding to neurons, HT22 cells, and purified *β*1-integrin as effectively as the loss of *β*1-integrin (**a** and **b**) FITC-A*β*42~O~ (100 nM, 1 h) binding to DIV21 primary hippocampal neurons with/without prior treatment (1 h) of control IgG, MAB1965 (*β*1-integrin allosteric modulator, 1 : 250), HUTS-4 (*β*1-integrin allosteric activator, 1 : 250), and/or 6D11 (PrP^c^ blocking, 1 : 50) monoclonal antibodies. Bottom panel magnified from regions of white rectangles. (**b**) Quantification of FITC-A*β*42~O~ binding (*n*⩾5 replicates, ANOVA, *post hoc* Tukey, ^\#^*P*\<0.0005 compared with control IgG). Error bars represent S.E.M. (**c**--**e**) FITC-A*β*42~O~ (100 nM, 1 h) binding to *β1-integrin fl/fl* neurons transduced with Lenti-mRFP (cont) or Lenti-Cre-mRFP (*β*1 cKO). (**d**) Quantification of FITC-A*β*42~O~ binding (*n*=5 replicates, *T*-test, ^\#^*P*\<0.0005). (**e**) Representative blots of *β*1-integrin from cKO (Lenti-Cre-mRFP) *versus* cont (Lenti-mRFP) neurons (all neurons including nontransduced). (**f**) Conditioned medium from CHO cells transfected with *β*1-integrin-Fc affinity purified with anti-Fc affinity column, sequentially eluted, and immunoblotted with anti-Fc. (**g**) Purified *β*1-integrin-Fc from fractions 1 and 2 captured by 96-well plates coated with anti-Fc IgG, subjected to biotin-A*β*42~O~ binding and/or incubated with different cations (MgCl~2~, 5 mM and MnCl~2~, 0.5 mM). (**h**) *K*~d~=10.3 nM with MgCl~2~. Two-way ANOVA *post hoc* Bonferroni, *n*=4 replicates, ^\#^*P*\<0.0005. (**h** and **i**) HT22 cells treated with FITC-A*β*42~O~ (0.1 *μ*M, 2 h) and/or *β*1-integrin blocking IgG (MAB1965, 1 : 500), MnCl~2~ (0.5 mM), or MgCl~2~ (5 mM), and subjected fluorescence microscopy. (**h**) Representative images of FITC-A*β*42~O~ binding/uptake show inhibition by MAB1965 antibody and MnCl~2~. (**i**) Quantification of mean intensities of FITC-A*β*42~O~ binding/uptake (*n*=4 replicates, ANOVA, *post hoc* Tukey, \*\**P*\<0.005 compared with FITC-A*β*42~O~ alone)](cdd20155f2){#fig2}

![Essential role of *β*1-integrin in A*β*42~O~-induced Cofilin activation as well as reciprocal requirement of Cofilin in A*β*42~O~-induced depletion of surface *β*1-integrin and F-actin-associated FCs (Vinculin and Talin). (**a** and **b**) DIV14 cortical WT or *β*1-integrin cKO neurons (transduced with Lenti-Cre) treated with/without A*β*42~O~ (1 *μ*M, 2 h) and subjected to immunoblotting. Note the decrease in p-Cofilin by A*β*42~O~ in WT but not in *β*1 cKO neurons (*n*=4 replicates, *T*-test, \**P*\<0.05). Error bars represent S.E.M. (**c**) HT22 cells transfected with control or Cofilin siRNA, treated with A*β*42~o~ (1 *μ*M, 2 h) and subjected cell surface biotinylation followed by direct immunoblotting or IP with anti-biotin and immunoblotting. Note that Cofilin knockdown prevents A*β*42~O~-induced depletion of surface *β*1-integrin. (**d** and **e**) HT22 cells transfected with control or Cofilin siRNA and subjected to cell surface biotinylation followed by direct immunoblotting or IP with anti-biotin and immunoblotting. (**d**) A representative experiment showing a dramatic increase in surface *β*1-integrin but no change in surface PrP^c^ after Cofilin knockdown. (**e**) Quantification of *β*1-integrin normalized to total *β*1-integrin and surface PrP^c^ normalized to total PrP^c^ (*n*=4 replicates, *T*-test, ^\#^*P*\<0.0005). (**f** and **g**) DIV21 hippocampal primary neurons treated with/without A*β*42~O~ (1 *μ*M, 2 h) and subjected to staining for Vinculin, F-actin (rhodamine-phalloidin), and DAPI. Note the near complete co-localization of Vinculin with F-actin, particularly in dendritic spines and loss of Vinculin immunoreactivity with A*β*42~O~ treatment. (**g**) Quantification of focal Vinculin mean intensity (FC Vinculin) in dendrites and dendritic spines after subtracting the mean diffuse cytosolic intensity in dendrites (*n*=5 replicates, *T*-test, ^\#^*P*\<0.0005). Error bars represent S.E.M. (**h** and **i**) DIV14 cortical WT and *Cofilin*^+/−^ neurons treated with/without A*β*42~O~ (1 *μ*M), subjected to separation of cytosol and FC-enriched fractions followed by immunoblotting. (**h**) Representative blots showing A*β*42~O~-induced depletion FC Vinculin and Talin in WT but not in *Cofilin*^+/−^ neurons. (**i**) Quantification of FC Vinculin and Talin after 2 h A*β*42~O~ treatment normalized to respective vehicle treated controls at 100%. (*n*=3 replicates, *T*-test, \**P*\<0.05, \*\**P*\<0.01). (**j** and **k**) Eight-month-old APP/PS1 transgenic mice and their nontransgenic littermates (WT) stereotaxically injected with 2 *μ*l *β*1-integrin blocking antibody (MAB1965, diluted 1 : 10) into the left hippocampus and 2 *μ*l control IgG (control ascites fluid, diluted 1 : 10) into the right hippocampus and subjected to immunohistochemistry for Vinculin 48 h post injection. (**j**) Representative images of Vinculin FCs (red) in the CA3 of the hemisphere injected with *β*1-integrin blocking antibody compared with the control IgG injected contralateral hemisphere. Focal Vinculin threshold adjusted to convert highest intensity signals from green to red puncta without altering diffuse cytosolic signal. (**k**) Quantification of focal Vinculin area and size normalized to control IgG (*n*=5 mice, 2 M and 3 F, *T*-test, \*\**P*\<0.005)](cdd20155f3){#fig3}

![Essential roles of Cofilin and *β*1-integrin in A*β*42~O~-induced depletion of F-actin and associated synaptic proteins in primary hippocampal neurons. (**a** and **b**) WT and *Cofilin*^+/−^ DIV21 hippocampal neurons treated with/without A*β*42~O~ (1 *μ*M, 2 h) and stained for F-actin (rhodamine-phalloidin), Drebrin, or PSD95. (**b**) Quantification of mean intensities of Drebrin, PSD95, and F-actin in spine-containing neurites (*n*=4--6 replicates, ANOVA, *post hoc* Tukey, \**P*\<0.05, \*\**P*\<0.005, ^\#^*P*\<0.0005). Error bars represent S.E.M. (**c** and **d**) DIV21 hippocampal neurons treated with/without A*β*42~O~ (1 *μ*M, 2 h) and/or control IgG or *β*1-integrin IgG (MAB1965) and stained for PSD95 and F-actin (rhodamine-phalloidin). (**c**) Representative images showing depletion of PSD95 and F-actin after A*β*42~O~ treatment, which is prevented by MAB1965. (**d**) Quantification of mean PSD95 and F-actin intensities in spine-containing neurites (*n*⩾6 replicates, ANOVA, *post hoc* Tukey, \**P*\<0.05, \*\**P*\<0.005)](cdd20155f4){#fig4}

![Requirement of Slingshot-1 (SSH1) in A*β*42~O~-induced Cofilin translocation to mitochondria and accumulation of mitochondrial Cofilin in AD brains. (**a** and **b**) HT22 cells treated with/without A*β*42~O~ (1 *μ*M) for the indicated times and subjected to separation of mitochondria and cytosol fractions followed by immunoblotting for the indicated proteins. (**a**) Representative blots showing Cofilin dephosphorylation (cytosol) and translocation to mitochondria (mito) after A*β*42~O~ treatment. (**b**) Quantification of cytosolic and mitochondrial Cofilin (*n*=4 replicates, *T*-test, \*\**P*\<0.005, ^\#^*P*\<0.0005). (**c**) HT22 cells transfected with control or SSH1 siRNA, treated with/without A*β*42~O~ (1 *μ*M, 4 h), and subjected to separation of cytosol *versus* mitochondria followed by immunoblotting for the indicated proteins. Note that SSH1 siRNA prevents A*β*42~O~-induced Cofilin dephosphorylation and translocation to mitochondria (*n*=4 replicates, ANOVA, *post hoc* Tukey, ^\#^*P*\<0.0005). (**d** and **e**) Mitochondria isolated from mid-frontal cortex of AD (*n*=5) and cognitively NC (*n*=4) and immunoblotted for Cofilin and Timm50 with or without DTT in sample buffer. (**d**) Representative blots showing abundance of Cofilin monomers (Cof~M~), dimers (Cof~Di~), trimers (Cof~Tri~), and high molecular weight species (Cof~H~) in AD (blot on left run without DTT). Samples with asterisk (\*) run with DTT and boiling show reduction of oxidized Cofilin oligomers to collapsed monomers (blot on right). (**e**) Quantification of Cofilin total (all four Cofilin bands), oligomers (Cof~Di~, Cof~Tri~, and Cof~H~), and monomers (Cof~M~) (*T*-test, \**P*\<0.03)](cdd20155f5){#fig5}

![A*β*42~O~-induced ROS production, mitochondrial dysfunction, and apoptosis via the *β*1-integrin--SSH1--Cofilin activation pathway. (**a** and **b**) HT22 cells treated with vehicle or A*β*42~O~ (1 *μ*M) for 2 h with or without 1 h prior treatment with Nox inhibitor (VAS2870, 40 nM), HUTS-4 (*β*1-integrin allosteric activating IgG, 1 : 250), or MAB1965 (*β*1-integrin allosteric modulating IgG, 1 : 250) and subjected to live-cell imaging for JC-1 (mitochondrial membrane potential, green/red ratio), Mitosox-Red (mitochondrial superoxide indicator), or H2DCF (general ROS indicator). Note that *β*1-integrin conformational modulation or inhibition of Nox significantly reduces A*β*42~O~-induced mitochondrial dysfunction and overall ROS increase. Representative H2DCF images are shown in [Supplementary Figure S6A](#sup1){ref-type="supplementary-material"}. (**b**) Quantification of JC-1 green/red ratio, Mitosox-Red, and H2DCF intensities (*n*=6, 1-way ANOVA, *post hoc* Tukey, \**P*\<0.05, \*\**P*\<0.01, or ^\#^*P*\<0.005 compared with A*β*42~O~. (**c** and **d**) HT22 cells transiently transfected with control or SSH1 siRNA, treated with / without A*β*42~O~ (1 *μ*M, 18 h) in 1% FBS medium, and subjected to FITC Annexin V/propidium iodide (PI) staining and fluorescence confocal microscopy. (**c**) Representative images showing reduction in Annexin V (early apoptosis) and PI (late apoptosis) staining in cells transfected with SSH1 siRNA (with A*β*42~O~). (**d**) Quantification of Annexin V/PI staining (*n*=4 replicates, ANOVA, *post hoc* Tukey, \**P*\<0.05, \*\**P*\<0.005, ^\#^*P*\<0.0005). (**e** and **f**) Seven-month-old WT and APP/PS1 littermate mouse frontal cortex homogenates (1% Triton X-100) immunoprecipitated for pan-14-3-3 or SSH1 and immunoblotted for SSH1 or Cofilin. Same brain samples also directly immunoblotted for the indicated proteins. (**e**) Representative blots showing decreased 14-3-3/SSH1 complex and increased SSH1/Cofilin complex in APP/PS1 mice. (**f**) Quantification of SSH1/14-3-3 complex, Cofilin/SSH1 complex, p-Cofilin, and total Cofilin (*n*=4 mice/genotype, 2 M and 2 F, *T*-test, \**P*\<0.02, \*\**P*\<0.005)](cdd20155f6){#fig6}

![Cofilin reduction rescues APP/A*β*-induced gliosis and loss of synaptic proteins as well as LTP and contextual memory deficits in APP/PS1 mice. (**a** and **b**) Seven-month-old WT, APP/PS1, and APP/PS1;C*ofilin*^+/−^ mice immunostained for GFAP, Synapsin I, and PSD95. (**a**) Representative images showing that Cofilin reduction ameliorates astrogliosis and synaptic damage associated with APP/PS1 mice. (**b**--**d**) Quantification of mean PSD95 and Synapsin I intensities in the stratum lucidum (SL) (*n*=4 mice/genotype, 2 F and 2 M, ANOVA, *post hoc* Tukey, \**P*\<0.05, ^\#^*P*\<0.0005). (**c**--**e**) Stimulating electrode placed in the Schaffer collaterals of the hippocampus and recording glass electrode positioned at the CA1 stratum radiatum below the pyramidal cell layer. (**c**) Input/output analysis generated by stepping up stimulation amplitude from 1 to 15mV in WT, APP/PS1, and APP/PS1;*Cofilin*^+/−^ acute slices. No significant differences observed (*n*=24 slices from four mice, APP/PS1: 19 slices from four mice, APP/PS1;*Cofilin*^+/−^: *n*=20 slices from three mice). (**d**) PPF showing no significant differences across genotypes and interstimulus interval except between APP/PS1;*Cofilin*^+/−^ and WT slices at the 40-ms interstimulus interval (two-way ANOVA, *post hoc* Bonferroni, \**P*\<0.05; WT: *n*=32 slices from four mice, APP/PS1: *n*=31 slices from four mice, APP/PS1;*Cofilin*^+/−^: *n*=25 slices from three mice). (**e**) LTP induced by the TBS showing significant differences in fEPSP slope in APP/PS1 compared with WT and APP/PS1;*Cofilin*^+/−^ slices (two-way ANOVA, *post hoc* Bonferroni, *P*\<0.0001 at all time points). (WT: *n*=28 slices from four mice, APP/PS1: *n*=33 slices from four mice, APP/PS1;*Cofilin*^+/−^: *n*=20 slices from three mice). Error bars represent S.E.M. (**f**) Percentage of time spent freezing during training period on day 1 (no significant differences observed by one-way ANOVA or Kruskal--Wallis statistic; WT *n*=12, APP/PS1 *n*=8, APP/PS1;*Cofilin*^+/−^ *n*=6; equal distribution of gender). Error bars represent S.E.M. (**g**) Percentage of time spend freezing during contextual fear conditioning (FC) on day 2 (Kruskal--Wallis statistic=9.66, *P*=0.008, genotypes=3, values=26; *post hoc* Dunn\'s, \**P*\<0.05; WT *n*=12, APP/PS1 *n*=8, APP/PS1;*Cofilin^+/−^ n*=6; equalized distribution of gender). (**h**) Percentage of time spent freezing during cued fear conditioning (FC) freezing on day 2 (no significant differences observed by one-way ANOVA or Kruskal--Wallis statistic; WT *n*=12, APP/PS1 *n*=8, APP/PS1;*Cofilin*^+/−^ *n*=6; equalized distribution of gender). (**i**) Total time spent on rotarod test (no significant differences observed by one-way ANOVA or Kruskal--Wallis statistic; WT *n*=11, APP/PS1 *n*=7, APP/PS1;*Cofilin*^+/−^ *n*=5; equalized distribution of gender). (**j**) Total distance traveled during open-field test (no significant differences observed by one-way ANOVA or Kruskal--Wallis statistic; WT *n*=11, APP/PS1 *n*=7, APP/PS1;*Cofilin*^+/−^ *n*=5; equalized distribution of gender). (**k**) Total time spent immobile during open-field test (no significant differences observed by 1-way ANOVA or Kruskal--Wallis statistic; WT *n*=11, APP/PS1 *n*=7, APP/PS1;*Cofilin*^+/−^ *n*=5; equalized distribution of gender)](cdd20155f7){#fig7}
